Monday, August 3, 2026
← Back to archivePolicy
Policy•Endpoints News•Aug 2, 2026
AstraZeneca, Bristol Myers in talks about merger — report
background ▾
- •Potential merger between AstraZeneca and Bristol Myers Squibb would be one of the largest pharma M&A transactions ever
- •Combined entity would possess substantial scale across oncology, immunology, and cardiovascular therapeutic areas
- •Regulatory and antitrust review timelines, final deal terms, and integration strategy remain to be determined
AstraZenecaBristol Myers Squibb
→ Read original articlePolicy•STAT News•Aug 3, 2026
Opinion: I’m a neurologist. I’ve delivered ALS diagnoses. Then I received one myself
background ▾
- •ALS diagnosis is frequently delayed even in well-resourced, well-insured populations due to unfamiliarity with early signs and physician discomfort with the diagnosis, extending decision uncertainty for patients
Policy•STAT News•Aug 3, 2026
Opinion: We lead the Federation of State Medical Boards. Here’s what we think about licensing AI to practice medicine
background ▾
- •FSMB explicitly rejects independent AI licensing, positioning AI as a regulated tool under physician accountability rather than as a separate practitioner—a stance that will shape emerging state-level AI regulation
- •Failed 2024 legislation in Idaho and Iowa reveals imminent policy risk: multiple states are actively considering separate AI licensing frameworks outside traditional medical boards, creating regulatory fragmentation risk
- •Watch for: state-level AI licensing proposals in 2025, interplay between FSMB guidance and actual state legislation, and how medical boards operationalize physician accountability for AI-related harms
Federation of State Medical Boards
→ Read original articlePolicy•KFF•Jul 31, 2026
Five Key Facts About People Experiencing Homelessness
background ▾
Policy•Fierce Biotech•Jul 31, 2026
Chutes & Ladders—Legend CEO departs without successor in place
background ▾
- •Legend Biotech CEO departure creates near-term leadership uncertainty, though the company emphasized no operational or financial disagreements precipitated the move
Legend BiotechSarepta TherapeuticsNasus PharmaCarvyktiTSRA-196Rinvoq
→ Read original articleMarket Access
Market Access•Endpoints News•Aug 1, 2026
Alnylam's slump deepens; Q2 earnings roundup; and more
background ▾
- •Alnylam's financial performance deteriorated in Q2, indicating potential commercial headwinds or pipeline challenges
Alnylam
→ Read original articleMarket Access•Fierce Biotech•Jul 31, 2026
From Abu Dhabi to Brazil, every region is vying for the ‘new emerging economy’ of biotech
background ▾
- •Abu Dhabi's HELM cluster and 5-million-specimen biobank, coupled with its rare disease prevalence due to consanguinity, position it as a differentiated hub for gene therapy development and diverse clinical trial recruitment.
- •Both Abu Dhabi and Brazil are exploiting population diversity and underrepresented ethnic groups in Western trials to address a persistent biotech bottleneck: assembling clinically representative trial cohorts.
Vesper Biotechnologies
→ Read original articleMarket Access•Endpoints News•Jul 31, 2026
AbbVie touts strong momentum for Skyrizi despite rising competition
background ▾
- •AbbVie reports continued strong performance for Skyrizi amid growing competitive threats in immunology
AbbVieSkyrizi
→ Read original articleMarket Access•Fierce Biotech•Jul 30, 2026
Boston Scientific cuts guidance again after unveiling restructuring plan
background ▾
- •Boston Scientific faces sustained competitive headwinds in core franchises (electrophysiology vs. Abbott/J&J, Watchman slowdown) that management expects to persist through 2027, suggesting market share pressure rather than temporary disruption
- •Two consecutive quarterly guidance cuts signal deteriorating visibility and forecasting confidence, raising questions about management's strategic positioning in high-growth medtech segments
- •Monitor 2028 guidance revisions and restructuring execution metrics, particularly whether the $500M cost savings and reinvestment strategy successfully arrest competitive losses or merely manage decline
Boston ScientificAbbottJohnson & JohnsonWatchman
→ Read original articleMarket Access•KFF•Jul 28, 2026
How Has ACA Marketplace Enrollment Changed Across States in 2026?
background ▾
- •ACA Marketplace effectuated enrollment fell 12% year-over-year (2.6 million people) in 2026 when enhanced federal premium tax credits expired, reversing seven consecutive years of growth and marking the largest single-year decline since the Marketplaces opened.
- •Average net premium payments surged 58% for 2026 enrollees without enhanced credits, with cost cited by 80% of enrollees who changed or dropped coverage and 17% of continuing enrollees worried about affording premiums year-round.
- •State-level variation in enrollment trends demonstrates the critical role of subsidies: New Mexico's 14% enrollment growth through its replacement state subsidy program contrasts sharply with widespread declines elsewhere, signaling that coverage sustainability depends on continuous financial support mechanisms.
Clinical Trials
Clinical Trials•STAT News•Aug 3, 2026
Heart transplant candidates fail if they get too weak. New program tries inpatient prehab
background ▾
- •56-62% of initially ineligible heart transplant candidates regained sufficient fitness to meet listing criteria through inpatient prehab, addressing frailty-based disqualification
- •The program directly counters the well-documented phenomenon where one day of bed rest requires three days of recovery, preventing patient deconditioning during critical waiting periods
- •Monitor for broader adoption across transplant centers and potential impact on overall transplant waitlist qualification rates and post-transplant outcomes
Banner–University Medical Center Phoenix
→ Read original articleClinical Trials•Fierce Biotech•Jul 31, 2026
Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail
background ▾
- •Zeus trial missed primary endpoint with hazard ratio of 0.99 versus the clinically significant 0.85 (15% benefit) that analysts had modeled, eliminating a projected multibillion-dollar opportunity in inflammation-driven cardiovascular disease
- •Novo's remaining hopes rest on Artemis and Hermes trials (data expected H1 2025), but BMO Capital Markets now views positive outcomes as unlikely following Zeus failure
- •Analysts suggest Novo may accelerate M&A activity in cardiovascular, metabolic, or rare disease to offset pipeline disappointment and reduce investor focus on GLP-1 dependency
Novo Nordiskziltivekimab
→ Read original articleClinical Trials•Endpoints News•Jul 31, 2026
Moderna's norovirus vaccine readout is delayed because of too few infections
background ▾
- •Moderna's norovirus vaccine efficacy readout delayed due to lower-than-expected infection rates in the trial population
- •Additional trial cohort being enrolled to generate sufficient efficacy data, with results expected after the next norovirus season
ModernaModerna norovirus vaccine
→ Read original articleClinical Trials•Endpoints News•Jul 31, 2026
Novo Nordisk rocked by late-stage cardiovascular drug failure
background ▾
- •Phase 3 failure of an anti-inflammatory cardiovascular agent challenges the inflammatory hypothesis as a therapeutic target in heart disease
- •Significant setback for Novo Nordisk's cardiovascular pipeline with potential impact on R&D strategy and investor confidence in this mechanism class
- •Clarification needed on whether failure was mechanism-related or compound-specific, and whether the program will be discontinued or redesigned
Novo Nordisk
→ Read original articleClinical Trials•Endpoints News•Jul 31, 2026
Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPO
background ▾
- •Ratio Therapeutics secured $70M Series C to fund radiopharmaceutical clinical development, indicating continued investor confidence in this emerging modality
- •Radiopharmaceutical sector continues attracting capital as a differentiated approach to targeted cancer therapy and molecular imaging
Ratio TherapeuticsVogenxDuquesne Family Office
→ Read original article